Related Experiment Video
Updated: Jan 9, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Construction and validation of an oxidative phosphorylation-related gene signature in lung squamous cell carcinoma
Ninghuang Dai1,2, Chen Fang3, Yu Gu1
1Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background:
Metabolic reprogramming, particularly toward oxidative phosphorylation (OXPHOS), is a hallmark of lung squamous cell carcinoma (LUSC) and contributes to its aggressive phenotype and immunosuppressive microenvironment. While OXPHOS activation is increasingly recognized as a key metabolic feature in LUSC, its prognostic implications and associated gene signatures remain underexplored. This study aimed to identify OXPHOS-related differentially expressed genes (DEGs) and construct a robust prognostic signature for LUSC.
Methods:
Using GEO datasets, we developed an OXPHOS-related prognostic signature via ssGSEA, differential analysis, and LASSO-Cox regression.
Results:
An 8-gene OXPHOS-related signature (LTBP1, MFGE8, ACTN1, CD59, CDC25C, SAAL1, SFXN4, PTTG1) was identified. High-risk patients exhibited significantly shorter overall survival than low-risk patients across all cohorts. The model demonstrated strong predictive accuracy for 1-, 3-, and 5-year survival. Notably, the high-risk group showed enriched pathways related to tumor stemness and immunosuppression.
Conclusion:
We developed and validated a novel OXPHOS-based gene signature that effectively stratifies LUSC patients by risk. This signature highlights the clinical relevance of OXPHOS in LUSC prognosis and may guide personalized therapeutic strategies targeting metabolic vulnerabilities. Study limitations include its retrospective design and lack of experimental validation.
